Regression of brain metastases from breast cancer with eribulin: a case report

BACKGROUND: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Matsuoka, Hiromichi, Tsurutani, Junji, Tanizaki, Junko, Iwasa, Tsutomu, Komoike, Yoshifumi, Koyama, Atsuko, Nakagawa, Kazuhiko
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2013
Soggetti:
Case Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3878316/
https://ncbi.nlm.nih.gov/pubmed/24350786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-541
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi